Intercede has reported prelims in line with the April trading update, detailing revenue growth of 25% to £11.0m. Forecasts continue to assume 30% growth into FY17 and FY18 in line with the board's strategic ambitions to 2020, and a target of EBITDA and cash flow breakeven as profit is reinvested in further R&D. With new products MyTAM and RapID generating less than 5% of revenue and material growth all therefore currently derived from the existing profitable MyID product set, we loo
07 Jun 2016
Prelims highlight opportunity
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Prelims highlight opportunity
Intercede Group plc (IGP:LON) | 110 0 0.0% | Mkt Cap: 64.1m
- Published:
07 Jun 2016 -
Author:
Andrew Darley -
Pages:
12
Intercede has reported prelims in line with the April trading update, detailing revenue growth of 25% to £11.0m. Forecasts continue to assume 30% growth into FY17 and FY18 in line with the board's strategic ambitions to 2020, and a target of EBITDA and cash flow breakeven as profit is reinvested in further R&D. With new products MyTAM and RapID generating less than 5% of revenue and material growth all therefore currently derived from the existing profitable MyID product set, we loo